RESULTS OF THE EMPA-REG OUTCOME™ STUDY

Thursday, 17 September 2015 - 17:15 - 18:45

Download complete slide kit here
CHAIRPERSON

Hellerström

PRESENTATIONS IN THIS SESSION:
DISCUSS:
Paramesh Shamanna
The benefit of empa appeared as early as 3 months and continued throughout the study why is it that no unblinded commitee or an interim analysis result in termination of the study for ethical reasons so as to deprive the patients on placebo
Jorge Polonia
These fantastic results remind me First the study of LCZ 696 in heart failure study PARADIGM-HF in which RAS in blocked and BNP is increased - Is it possible that empa increases the availability of BNP? Second, I think we are revising the concept of metabolic syndrome. Small but effective reduction of HBA1C weight and blood pressure may be the clue for the success of that broad and multi factor effect. It appears to be a new drug with a new concept of intervention in cardiometabolic disease Jorge Polonia (Prof) Portugal
Jacob Marquardt
The audio quality of the webcast will be improved soon. Appologies for that.
Dr. Samir Abou-Hussein
Why the population consisted mainly of males? Is this can be considered improper design of the study regarding the gender distribution in this study?
Christopher Walton
works on my iphone but froze on my pc
COMMENT ON THIS SESSION: